Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vaxil Bio ( (TSE:VXL) ) just unveiled an announcement.
Vaxil Bio Ltd. has completed a non-brokered private placement, raising $140,000, which will be used to explore strategic options beyond the healthcare sector. The company has also announced changes to its board of directors, with the resignation of Mr. Ari Kellen and Mr. Shawn Langer and the appointment of Mr. Simon Igelman, a corporate transactional lawyer, as it seeks new strategic opportunities to benefit shareholders.
Spark’s Take on TSE:VXL Stock
According to Spark, TipRanks’ AI Analyst, TSE:VXL is a Underperform.
Vaxil Bio’s overall score is primarily driven by its significant financial challenges, including a lack of revenue, persistent losses, and cash flow difficulties. The stable balance sheet with no debt is a positive aspect but is overshadowed by operational inefficiencies. Technical analysis indicators are absent, providing no clarity on stock trends, while valuation concerns arise from negative earnings. The absence of earnings call data and corporate events further reduces the score’s potential uplift.
To see Spark’s full report on TSE:VXL stock, click here.
More about Vaxil Bio
Vaxil Bio Ltd. was an immunotherapy biotech company focused on targeting prominent cancer markers and infectious diseases. Its lead product was ImMucin™, which had received orphan drug status from the FDA and EMA. The company is currently evaluating other business opportunities, which may or may not be in the biotechnology industry, to enhance shareholder value.
Average Trading Volume: 4,003
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$383.5K
For detailed information about VXL stock, go to TipRanks’ Stock Analysis page.